Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 8/20 | 0.53 |
| ▸ | JUN | P05412 | 7/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 7/20 | 0.53 |
| ▸ | RELA | Q04206 | 7/20 | 0.53 |
| ▸ | FOS | P01100 | 5/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ATF1 | P18846 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8543216 | 0.92 | KDM4E (0.72) | KDM4ENFKB1JUNNFKB2RELA | |
| SCHEMBL21341724 | 0.90 | KDM4E (0.55) | KDM4ENFKB1JUNNFKB2RELA | |
| SCHEMBL12775469 | 0.89 | KDM4E (0.61) | KDM4ENFKB1JUNNFKB2RELA | |
| SCHEMBL2354109 | 0.88 | KDM4E (0.67) | KDM4ENFKB1JUNNFKB2RELA | |
| SCHEMBL2352548 | 0.85 | KDM4E (0.64) | KDM4ENFKB1JUNNFKB2RELA | |
| SCHEMBL2119119 | 0.84 | KDM4E (0.74) | KDM4ENFKB1JUNNFKB2RELA | |
| SCHEMBL4592592 | 0.83 | KDM4E (0.72) | KDM4ENFKB1JUNNFKB2RELA | |
| SCHEMBL25415290 | 0.82 | KDM4E (0.71) | KDM4ENFKB1JUNNFKB2RELA | |
| SCHEMBL3922065 | 0.82 | KDM4E (1.00) | KDM4ENFKB1JUNNFKB2RELA | |
| Water SCHEMBL4592788 | 0.82 | KDM4E (0.71) | KDM4ENFKB1JUNNFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963445-B2 | Chemical compounds | SYNGENTA LIMITED (GB) | 2018-05-08 | — | — | US | disclosed |
| US-9963445-B2 | Chemical compounds | SYNGENTA LIMITED (GB) | 2018-05-08 | — | — | US | disclosed |
| US-20160159781-A1 | CHEMICAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-09 | — | — | US | disclosed |
| US-20120289540-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8188113-B2 | For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289540-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | BRAF, PRKDC, RAF1 | KDM4E 2009/4885NFKB1 1539/4885JUN 1691/4885 |
| US-20160159781-A1 | CHEMICAL COMPOUNDS | DDT, CBR3, CYP1B1 | KDM4E 953/4885NFKB1 2759/4885JUN 3749/4885 |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | KDM4E 2009/4885NFKB1 1539/4885JUN 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.